Endologix LLC, a prominent player in the medical device industry, is headquartered in the United States and focuses on innovative solutions for vascular diseases. Founded in 1992, the company has made significant strides in the development of advanced endovascular technologies, particularly for the treatment of abdominal aortic aneurysms (AAAs). Endologix is renowned for its unique product offerings, including the AFX® Endovascular AAA System and the Ovation® iX Abdominal Stent Graft System, which are designed to enhance patient outcomes through minimally invasive procedures. With a strong presence in North America and expanding operations in Europe, Endologix has established itself as a leader in the vascular intervention market, consistently recognised for its commitment to quality and innovation.
How does Endologix LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Endologix LLC's score of 17 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Endologix LLC, headquartered in the US, currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As a result, there is no information on their climate commitments or reduction initiatives at this time. The absence of emissions data and reduction targets suggests that Endologix LLC may still be in the early stages of developing a comprehensive climate strategy.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Endologix LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
